​

Taysha Gene Therapies (TSHA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TSHA Stock Forecast

Taysha Gene Therapies (TSHA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $18.67, with a high of $44.00 and a low of $5.00. This represents a 1405.65% increase from the last price of $1.24.

- $9 $18 $27 $36 $45 High: $44 Avg: $18.67 Low: $5 Last Closed Price: $1.24

TSHA Stock Rating

Taysha Gene Therapies stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

TSHA Price Target Upside V Benchmarks

TypeNameUpside
StockTaysha Gene Therapies1405.65%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$6.67
Last Closing Price$1.24$1.24$1.24
Upside/Downside--437.90%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2537---10
Mar, 2547---11
Feb, 2547---11
Jan, 2547---11
Dec, 2447---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Keith TapperBMO Capital$5.00$2.31116.45%303.23%
Jul 01, 2024Christopher RaymondPiper Sandler$7.00$2.24212.50%464.52%
May 14, 2024Eun YangJefferies$8.00$2.40233.33%545.16%
Apr 09, 2024Christopher RaymondRaymond James$9.00$2.68235.82%625.81%
Feb 01, 2023Jefferies$1.50$1.64-8.54%20.97%
Oct 19, 2021Matthew HarrisonMorgan Stanley$39.00$17.63121.21%3045.16%
May 19, 2021Kristen KluskaCantor Fitzgerald$44.00$21.78102.02%3448.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024Canaccord GenuityBuyBuyhold
Nov 12, 2024Piper SandlerOverweightOverweighthold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Jul 23, 2024NeedhamUnderperformUnderperformhold
Jul 01, 2024Piper SandlerOverweightOverweighthold
Jun 26, 2024BMO CapitalOutperforminitialise
May 28, 2024Piper SandlerMarket OutperformMarket Outperformhold
May 14, 2024JefferiesBuyupgrade
Apr 30, 2024NeedhamUnderperformUnderperformhold
Apr 09, 2024Piper SandlerMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.86$-0.96$-0.36----
Avg Forecast$-2.94$-1.47$-0.37$-0.38$-0.32$-0.35$-0.04
High Forecast$-2.20$-1.34$-0.36$-0.33$0.13$-0.25$-0.03
Low Forecast$-4.86$-1.59$-0.39$-0.44$-0.55$-0.42$-0.05
Surprise %31.29%-34.69%-2.70%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.50M$15.45M$8.33M----
Avg Forecast$8.18M$14.49M$8.25M$4.83M$28.03M$54.54M$153.55M
High Forecast$12.29M$15.90M$8.45M$5.96M$34.57M$67.26M$189.37M
Low Forecast$6.60M$13.06M$8.14M$4.07M$23.62M$45.96M$129.40M
Surprise %-69.42%6.65%1.06%----

Net Income Forecast

$-600M $-470M $-340M $-210M $-80M $50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-169.58M$-111.57M$-89.30M----
Avg Forecast$-341.83M$-170.03M$-43.60M$-44.76M$-24.73M$-38.45M$-4.26M
High Forecast$-255.91M$-155.90M$-41.76M$-38.87M$14.61M$-28.56M$-3.39M
Low Forecast$-564.93M$-184.16M$-45.44M$-50.65M$-64.08M$-48.33M$-5.55M
Surprise %-50.39%-34.38%104.81%----

TSHA Forecast FAQ

Is Taysha Gene Therapies stock a buy?

Taysha Gene Therapies stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Taysha Gene Therapies is a favorable investment for most analysts.

What is Taysha Gene Therapies's price target?

Taysha Gene Therapies's price target, set by 14 Wall Street analysts, averages $18.67 over the next 12 months. The price target range spans from $5 at the low end to $44 at the high end, suggesting a potential 1405.65% change from the previous closing price of $1.24.

How does Taysha Gene Therapies stock forecast compare to its benchmarks?

Taysha Gene Therapies's stock forecast shows a 1405.65% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Taysha Gene Therapies over the past three months?

  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Taysha Gene Therapies’s EPS forecast?

Taysha Gene Therapies's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.38, marking a 5.56% increase from the reported $-0.36 in 2024. Estimates for the following years are $-0.32 in 2026, $-0.35 in 2027, and $-0.04 in 2028.

What is Taysha Gene Therapies’s revenue forecast?

Taysha Gene Therapies's average annual revenue forecast for its fiscal year ending in December 2025 is $4.83M, reflecting a -42.04% decrease from the reported $8.33M in 2024. The forecast for 2026 is $28.03M, followed by $54.54M for 2027, and $153.55M for 2028.

What is Taysha Gene Therapies’s net income forecast?

Taysha Gene Therapies's net income forecast for the fiscal year ending in December 2025 stands at $-44.76M, representing a -49.88% decrease from the reported $-89.298M in 2024. Projections indicate $-24.731M in 2026, $-38.446M in 2027, and $-4.258M in 2028.